Company / Return on Equity (ROE)
C4 Therapeutics, Inc. Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-40.9%
FY2025
5-year range
-53.8% / -21.5%
FY2022-FY2025
Trend
+24.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
C4 Therapeutics, Inc. reports negative total equity of -40.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-40.9% in FY2025 with a 3-year CAGR of -19.4%.
Improved from -53.8% to -40.9% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -19.4pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 24.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -40.9% | +24.0% |
| FY2024 | -53.8% | +0.0% |
| FY2023 | -53.8% | -150.0% |
| FY2022 | -21.5% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026